Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Brain waves measured using a simple device just one week into treatment can indicate whether a depressed patient should continue taking a medication or be switched to another. The study, which was conducted at nine sites across the U.S., could significantly reduce the time it takes to effectively treat major depression.

“Selecting the right antidepressant medication is a bit of a shot in the dark,” says Andrew Leuchter, professor of psychiatry at UCLA and lead author of the study. “The first medicine we choose only gets the patient well about a third of the time.”

Antidepressants must be taken for approximately eight weeks before it’s clear whether or not the medicine will have an effect. Patients frequently have to try two to three medications before finding an effective one, meaning the search for the right medication can take many months. “This leads to prolonged disability, prolonged suffering, and the chance that the patient may never get well,” says Leuchter. “Some patients say, ‘I don’t need this,’ and drop out of treatment.” The testing process studied by Leuchter and his colleagues, which takes only 15 minutes, could help those suffering from depression find relief faster.

For the study, the researchers used a customized version of a quantitative electroencephalography (QEEG) system to study the brainwave patterns of 375 people suffering from major depression. The device, developed by Aspect Medical Systems of Norwood, MA, consists of a few electrodes mounted on a strap that is worn across the patient’s head. (Aspect Medical provided funding for the study and employs Leuchter as a consultant. Leuchter is also a minor shareholder in the firm.) The strap hooks up to a hockey-puck-size device that digitizes and filters the EEG signal, as well as performing some basic processing. That device plugs into a laptop computer, which does the bulk of the signal analysis.

Unlike a standard QEEG system, which requires bulky equipment and is often housed in its own lab, the Aspect Medical system is small and portable. Leuchter says the system doesn’t require a lot of specialized training like traditional QEEG systems, either; it took only a few hours to train staff to use the device. “The process is so simple, even a doctor can do it,” he says. While the device is still far from commercialization, the ultimate intent is to offer it to physicians.

Scientists measured brain activity before the patient was on any medication and then again one week after starting the popular antidepressant escitalopram, which targets a chemical messenger called serotonin. The patients were then randomly assigned to one of three groups: one group continued on escitalopram alone; one group was switched to another common antidepressant, bupropion, which acts on the chemical messengers norepinephrine and dopamine; and the third group took both medications.

2 comments. Share your thoughts »

Credit: Aspect Medical Systems

Tagged: Biomedicine, EEG, biomarkers, depression, brain mapping, antidepressant

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me